Biotech cancer-treatment developer Iovance Biotherapeutics Inc. IOVA on Friday said it had completed its rolling biologics license application submission to the U.S. Food and Drug Administration for lifileucel — a therapy intended to combat advanced melanoma in some cases. Interim Chief Executive Frederick Vogt said in a statement that completing the submission “is a critical step forward in our journey to deliver the first individualized, one-time cell therapy for a solid tumor.” He added: “Our preparations for commercialization remain on track to support a launch later this year.” Shares rose 13% after hours on Friday.